AE Wealth Management LLC boosted its stake in Edwards Lifesciences Corp (NYSE:EW) by 56.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,332 shares of the medical research company’s stock after acquiring an additional 1,201 shares during the quarter. AE Wealth Management LLC’s holdings in Edwards Lifesciences were worth $777,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. FormulaFolio Investments LLC purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $627,000. Honkamp Krueger Financial Services Inc. boosted its stake in shares of Edwards Lifesciences by 4.7% during the 4th quarter. Honkamp Krueger Financial Services Inc. now owns 1,015 shares of the medical research company’s stock valued at $237,000 after buying an additional 46 shares during the last quarter. Dubuque Bank & Trust Co. purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $241,000. Raymond James Trust N.A. boosted its stake in shares of Edwards Lifesciences by 2.6% during the 4th quarter. Raymond James Trust N.A. now owns 7,915 shares of the medical research company’s stock valued at $1,847,000 after buying an additional 202 shares during the last quarter. Finally, Tocqueville Asset Management L.P. lifted its stake in Edwards Lifesciences by 0.7% during the fourth quarter. Tocqueville Asset Management L.P. now owns 45,529 shares of the medical research company’s stock worth $10,621,000 after purchasing an additional 330 shares during the last quarter. Hedge funds and other institutional investors own 80.77% of the company’s stock.
In other Edwards Lifesciences news, VP Catherine M. Szyman sold 2,500 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $227.19, for a total value of $567,975.00. Following the sale, the vice president now directly owns 19,605 shares of the company’s stock, valued at $4,454,059.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael A. Mussallem sold 22,850 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $238.79, for a total value of $5,456,351.50. Following the completion of the sale, the chief executive officer now directly owns 95,770 shares in the company, valued at $22,868,918.30. The disclosure for this sale can be found here. Insiders sold 174,241 shares of company stock worth $40,929,955 over the last ninety days. 1.63% of the stock is owned by corporate insiders.
Shares of NYSE EW opened at $238.64 on Tuesday. Edwards Lifesciences Corp has a 1-year low of $162.81 and a 1-year high of $247.64. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.53 and a quick ratio of 2.74. The business’s fifty day moving average price is $235.48 and its two-hundred day moving average price is $224.27. The firm has a market capitalization of $49.77 billion, a PE ratio of 65.38, a P/E/G ratio of 2.62 and a beta of 0.77.
Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $1.41 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.19. Edwards Lifesciences had a return on equity of 32.28% and a net margin of 18.64%. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same period last year, the company earned $1.07 earnings per share. The firm’s revenue for the quarter was up 20.7% on a year-over-year basis. Equities research analysts expect that Edwards Lifesciences Corp will post 5.6 earnings per share for the current fiscal year.
Several equities analysts recently issued reports on the company. Piper Jaffray Companies raised their price objective on Edwards Lifesciences from $255.00 to $262.00 and gave the stock an “overweight” rating in a research note on Monday, December 9th. Oppenheimer upgraded Edwards Lifesciences from a “market perform” rating to a “buy” rating and set a $280.00 price objective on the stock in a research note on Thursday, January 9th. Royal Bank of Canada raised their price objective on Edwards Lifesciences from $217.00 to $250.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 22nd. Canaccord Genuity restated a “buy” rating and set a $260.00 price objective on shares of Edwards Lifesciences in a research note on Friday, December 6th. Finally, Cowen restated a “buy” rating and set a $275.00 price objective on shares of Edwards Lifesciences in a research note on Tuesday, December 17th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company. Edwards Lifesciences has an average rating of “Buy” and an average price target of $239.42.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Article: Learning About the VIX – Volatility Index
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.